Nanozyme-powered immunotherapy via concurrent niche disruption and checkpoint blockade for acute myeloid leukemia
Authors:
- Fei WangFWFei Wang
- Qianqian LiQLQianqian Li
- Yan WangYWYan Wang
- Xiaoli WeiXWXiaoli Wei
- Mingze LuMLMingze Lu
- Haoan WuHWHaoan Wu
- Ming MaMMMing Ma
- Yu ZhangYZYu Zhang
- 29 October 2026
- journal article
- Published by Elsevier in Acta Biomaterialia
Abstract
No abstract availableFunding Information
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
This publication has 44 references indexed in Scilit:
- Nanozyme-based synergistic therapeutic strategies against tumorsDrug Discovery Today, 2025
- Transition-metal-based nanozymes for biosensing and catalytic tumor therapyAnalytical and Bioanalytical Chemistry, 2024
- Nanoribbons of 2D materials: A review on emerging trends, recent developments and future perspectivesCoordination Chemistry Reviews, 2022
- Nanozyme for tumor therapy: Surface modification mattersExploration, 2021
- Stepwise evolution of therapy resistance in AMLCancer Cell, 2021
- Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid LeukemiaSmall, 2020
- Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic TargetsCurrent Oncology Reports, 2019
- Nanocatalysts promote Streptococcus mutans biofilm matrix degradation and enhance bacterial killing to suppress dental caries in vivoBiomaterials, 2016
- Epitope characterization of an anti‐PD‐L1 antibody using orthogonal approachesJournal of Molecular Recognition, 2015
- Maintenance of the Hematopoietic Stem Cell Pool by CXCL12-CXCR4 Chemokine Signaling in Bone Marrow Stromal Cell NichesImmunity, 2006